Your Twin learns with you

30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Jesus Melgarejo

Has grant

Assistant Professor

The University of Texas Rio Grande Valley
Country flagUnited States

Research Interests

Explore related searches

Recent Grants

Grant: Open

Study of 24-Hours Blood Pressure Data to Describe a Complex Cardiovascular Dynamic System Beyond Conventional Metrics

Open Date: 2025-04-01

Close Date: 2028-03-31

Articles (9)

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Aims Coronary artery disease (CAD) is multifactorial, caused by complex pathophysiology, and contributes to a high burden of mortality worldwide. Urinary proteomic analyses may help to identify predictive biomarkers and provide insights into the pathogenesis of CAD. Methods and results Urinary proteome was analysed in 965 participants using capillary electrophoresis coupled with mass spectrometry. A proteomic classifier was developed in a discovery cohort with 36 individuals with CAD and 36 matched controls using the support vector machine. The classifier was tested in a validation cohort with 115 individuals who progressed to CAD and 778 controls and compared with two previously developed CAD-associated classifiers, CAD238 and ACSP75. The Framingham and SCORE2 risk scores were available in 737 participants. Bioinformatic analysis was performed based on the CAD-associated peptides. The novel proteomic classifier was comprised of 160 urinary peptides, mainly related to collagen turnover, lipid metabolism, and inflammation. In the validation cohort, the classifier provided an area under the receiver operating characteristic curve (AUC) of 0.82 [95% confidence interval (CI): 0.78–0.87] for the CAD prediction in 8 years, superior to CAD238 (AUC: 0.71, 95% CI: 0.66–0.77) and ACSP75 (AUC: 0.53 and 95% CI: 0.47–0.60). On top of CAD238 and ACSP75, the addition of the novel classifier improved the AUC to 0.84 (95% CI: 0.80–0.89). In a multivariable Cox model, a 1-SD increment in the novel classifier was associated with a higher risk of CAD (HR: 1.54, 95% CI: 1.26–1.89, P < 0.0001). The new classifier further improved the risk reclassification of CAD on top of the Framingham or SCORE2 risk scores (net reclassification index: 0.61, 95% CI: 0.25–0.95, P = 0.001; 0.64, 95% CI: 0.28–0.98, P = 0.001, correspondingly). Conclusion A novel urinary proteomic classifier related to collagen metabolism, lipids, and inflammation showed potential for the risk prediction of CAD. Urinary proteome provides an alternative approach to personalized prevention.

Year:

2023

Collaborators (12)

Yan Cheng

Københavns Universitet

DENMARK
View details

Esther Lopez-Garcia

Full Professor

Universidad Autónoma de Madrid

SPAIN
View details

Dries Martens

Hasselt University

BELGIUM
View details

Claudia L Satizabal

Associate Professor

University of Texas Health Science Center at San Antonio

UNITED STATES
View details

Tine Hansen

Professor

Copenhagen University Hospital

DENMARK
View details

Kei Asayama

Professor

Teikyo University School of Medicine

JAPAN
View details

Takayoshi Ohkubo

Teikyo University

JAPAN
View details

Karlheinz Peter

MONASH UNIVERSITY

AUSTRALIA
View details

Silvia Mejia

Assistant Professor

The University of Texas Rio Grande Valley

UNITED STATES
View details

Valérie Tikhonoff

Docenti di ruolo di IIa fascia

University of Padua

ITALY
View details

Kristina Vatcheva

associate professor

The University of Texas Rio Grande Valley

UNITED STATES
View details

Zhen-Yu Zhang

Katholieke Universiteit Leuven

BELGIUM
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.